Becton Dickinson (BDX) Retirement News Puts Its Fair Value Narrative Back In Focus
Becton Dickinson (BDX) is back in focus after the company announced that long serving executive Michael D. Garrison plans to retire in October, prompting investors to reassess leadership and segment reporting.
See our latest analysis for Becton Dickinson.
Becton Dickinson’s share price has been choppy, with a 2.22% 1 day share price gain to US$156.36 and a year to date share price return down 19.79%. The 1 year total shareholder return of 10% indicates dividends and reinvestment have softened the longer term decline seen in the 3 and 5 year total shareholder return figures.
If leadership changes at Becton Dickinson have you reassessing healthcare exposure, this can be a useful moment to broaden your watchlist with 40 healthcare AI stocks.
With Becton Dickinson stock rebounding to US$156.36 yet trading below both intrinsic and analyst estimates, the gap between price and fair value is widening. How far away is the market from the underlying valuation range?
Most Popular Narrative: 13.7% Undervalued
Becton Dickinson's most followed narrative points to a fair value of $181.23 per share versus the last close at $156.36. This frames a double digit discount that hinges on how the portfolio and capital returns play out over time.
The pending separation of the Biosciences and Diagnostic Solutions business is expected to transform BD into a pure play medical technology leader with a consumables heavy portfolio (>90% of revenue). This structure is intended to enable higher cash flow predictability and margin improvement, while anticipated aggressive share buybacks are designed to directly support EPS growth.
Want to see what sits behind that fair value for Becton Dickinson? The narrative leans on specific revenue trends, margin shifts, and a richer earnings multiple that all have to line up. The full breakdown shows how those moving parts fit together.
Result: Fair Value of $181.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that story depends on execution, and Becton Dickinson still faces tariff and trade pressures, as well as potential disruption if the Biosciences and Diagnostics separation runs into cost or integration issues.
Find out about the key risks to this Becton Dickinson narrative.
Next Steps
If this mix of risks and potential rewards around Becton Dickinson leaves you unsure, take a closer look now and weigh the data for yourself with 5 key rewards and 2 important warning signs
Looking for more investment ideas beyond Becton Dickinson?
Before moving on from Becton Dickinson, consider broadening your options by reviewing other stocks with income potential, value characteristics, and balance sheet strength.
- Target steady cash payouts by reviewing companies in the 9 dividend fortresses and see which income opportunities fit your risk tolerance.
- Identify potential value opportunities by scanning the screener containing 19 high quality undiscovered gems that match your preferred quality and fundamentals.
- Emphasize resilience in challenging markets by focusing on companies from the 79 resilient stocks with low risk scores that align with your long term goals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com